(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied.
Related Topics
OCRA’s Early Career Investigator Grant Recipients
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued
OCRA’s Collaborative Research Development Grant & Microsoft AI for Health Grantees
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not … Continued
CDC Report Shows Drop in Cervical Precancer Among HPV Vaccinated Age Group
Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease … Continued